Mankind Pharma Announces Investor Conference Call for Q4FY26 on May 20

Mankind Pharma Limited has announced an investor conference call scheduled for Wednesday, May 20, 2026, at 12:00 PM IST. The call is being held pursuant to Regulation 30 & 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to discuss the business performance and financial results for the quarter and financial year ended March 31, 2026.

Earnings Call Details

The conference call will feature the company's senior management team to discuss Q4 and FY26 results. The session is scheduled to last from 12:00 PM to 01:00 PM IST. Participants can join via the Zoom webinar link provided by the company.

Earnings Call Details
Date	Wednesday, 20th May 2026
Time	12:00 PM – 01:00 PM IST
Zoom Call	https://us06web.zoom.us/webinar/register/WN_gjCF6TrYR9eK24zP-RYSZQ

Management Representation

The discussion will be led by key executives including Mr. Rajeev Juneja (Vice Chairman & Managing Director), Mr. Sheetal Arora (Chief Executive Officer & Whole Time Director), and Mr. Arjun Juneja (Chief Operating Officer). Other participants include Mr. Sudipta Roy (Senior President – Sales & Marketing), Mr. Ashutosh Dhawan (Global Chief Financial Officer), Mr. Prakash Agarwal (President - Strategy), and Mr. Abhishek Agarwal (Head - Investor Relations & Strategy).

Upcoming Board Meeting

This announcement follows the company's earlier intimation regarding a Board of Directors meeting scheduled for Tuesday, May 19, 2026. The Board will consider and approve the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. Additionally, the Board will deliberate on the realignment of security cover for existing Non-Convertible Debentures (NCDs) following the redemption of NCDs worth ₹1,250 Crores on April 16, 2026.

Trading Window Closure

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for the company's securities remains closed until May 21, 2026. The intimation was signed by Hitesh Kumar Jain, Company Secretary & Compliance Officer, on May 8, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.34%	+8.19%	+19.15%	+7.47%	-0.07%	+70.91%

Mankind Pharma continues to attract positive analyst attention as Morgan Stanley maintains its Overweight rating on the stock, setting a target price of ₹2500. The global investment bank's stance reflects confidence in the company's operational trajectory and its relative positioning within the domestic pharmaceutical formulations space.

Key Drivers Behind the Overweight Rating

Morgan Stanley's rationale is anchored in a combination of business recovery and operational improvements. The brokerage points to several factors underpinning its constructive view on the stock, as summarised below:

Parameter:	Details
Rating:	Overweight
Target Price:	₹2500
BSV Business:	Recovery underway
Deleveraging:	Ongoing
MR Activity:	Strengthening
Productivity:	Gains noted
Management Disruptions:	Viewed as transitory
Valuation vs. Peers:	Superior risk-reward support

Recovery and Operational Momentum

A notable highlight in Morgan Stanley's assessment is the recovery observed in the BSV business, which is seen as a meaningful contributor to the company's improving execution. Alongside this, the brokerage notes that ongoing deleveraging is strengthening the balance sheet profile, while stronger medical representative (MR) activity and productivity gains are reinforcing the commercial engine of the business.

Management Disruptions Seen as Transitory

Morgan Stanley acknowledges recent management disruptions at Mankind Pharma but characterises them as transitory in nature, suggesting the brokerage does not view these developments as a structural impediment to the company's performance outlook.

Valuation and Peer Comparison

The brokerage further notes that Mankind Pharma offers superior risk-reward and valuation support relative to other domestic formulation peers, positioning it favourably within the broader Indian pharmaceutical sector from a comparative standpoint.